Evidence Table D2. CONTINUOUS outcomes for class ANTI-BACTERIAL (TOPICAL)/KERATOLYTIC (TOPICAL).

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	D.01.01			**Benzoyl peroxide**		**Vehicle**		
173 ↑ Parallel	N=77 Mild/mod	**Inflammatory (count)** Count location: Face. Baseline counts: 44 (Target) / 44 (Comparator)	Short (4)	Percent Change*: -43		Percent Change*: -05	*NS*	
176 ↓ Parallel	N=150 Mod/sev	**Inflammatory change (%)** Count location: Face.	Short (4)	Percent change: -42		Percent change: -39		**NS**
173 ↑ Parallel	N=77 Mild/mod	**Non-inflammatory (count)** Count location: Face. Baseline counts: 48 (Target) / 49 (Comparator)	Short (4)	Percent Change*: -23	*.05*	Percent Change*: 02		
176 ↓ Parallel	N=150 Mod/sev	**Non-inflammatory change (%)** Count location: Face.	Short (4)	Percent change: -24		Percent change: -4		**NS**
173 ↑ Parallel	N=77 Mild/mod	**Severity (leeds)**	Short (4)	Measure: 1	*.01*	Measure: 1	*NS*	**0.01**
176 ↓ Parallel	N=150 Mod/sev	**Total lesions change (%)**	Short (4)	Percent change: -25		Percent change: -7		
241 ↑ Parallel	N=50 Mild/mod	**Total lesions change (%)**	Short (6)	Percent change: -44		Percent change: -3		**0.01**
		Total lesions change (%)	Mid (8)	Percent change: -51		Percent change: -18		**0.01**
173	N=77	**Inflammatory (count)** Count location: Face. Baseline counts: 44 (Target) / 44 (Comparator)	Mid (12)	Percent Change*: -52	*.01*	Percent Change*: 09	*NS*	**0.01**
176 ↓ Parallel	N=150 Mod/sev	**Inflammatory change (%)** Count location: Face.	Mid (12)	Percent change: -60	*.05*	Percent change: -10	*NS*	**0.05**
173 ↑ Parallel	N=77 Mild/mod	**Non-inflammatory (count)** Count location: Face. Baseline counts: 48 (Target) / 49 (Comparator)	Mid (12)	Percent Change*: -52	*.01*	Percent Change*: 06	*NS*	**0.01**
176 ↓ Parallel	N=150 Mod/sev	**Non-inflammatory change (%)** Count location: Face.	Mid (12)	Percent change: -30	*.02*	Percent change: -4	*NS*	**0.05**
173 ↑ Parallel	N=77 Mild/mod	**Severity (leeds)**	Mid (12)	Measure: 0	*.01*	Measure: 1		**0.01**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
176 ↓ N=150 Parallel Mod/sev		**Total lesions change (%)** Count location: Face.	Mid (12)	Percent change: -31	*.02*	Percent change: -5	*NS*	**NS**
	D.01.01			**Benzoyl Peroxide (20%)**		**Vehicle**		
314 N=59 Parallel Mod		**Total lesion (count)** Count location: Entire face. Baseline counts: 19 (Target) / 16 (Comparator)	Short (6)	Percent Change*: -58		Percent Change*: -25		
		Total lesion (count)	Mid (12)	Percent Change*: -53		Percent Change*: -25		
	D.01.03			**Benzoyl peroxide**		**Gluconolactone**		
176 ↓ N=150 Parallel Mod/sev		**Inflammatory change (%)** Count location: Face.	Short (4)	Percent change: -42		Percent change: -49		**NS**
		Non-inflammatory change (%)	Short (4)	Percent change: -24		Percent change: -8		**NS**
		Total lesions change (%)	Short (4)	Percent change: -25		Percent change: -15		
		Inflammatory change (%)	Mid (12)	Percent change: -60	*.05*	Percent change: -59	*.001*	**0.05**
		Non-inflammatory change (%)	Mid (12)	Percent change: -30	*.02*	Percent change: -17	*NS*	**0.05**
		Total lesions change (%)	Mid (12)	Percent change: -31	*.02*	Percent change: -22	*.05*	**NS**
	D.01.04			**Benzoyl peroxide**		**Salicylic acid**		
304 ↑ N=30 Cross-over Mild		**Comedones change [phase i] (%)** Count location: Undefined.	Short (2)	Percent change: -20	*NS*	Percent change: -34	*.01*	**NS**
		Comedones change [phase ii] (%)	Short (2)	Percent change: 10	*NS*	Percent change: -9	*.05*	**NS**
	D.01.05			**Benzoyl peroxide**		**Sulfur + resorcinol**		
272 N=189 Parallel		**Total lesions change (%)** Count location: Left side.	Long (14	Percent change: -32		Percent change: -16		
	D.01.09			**Benzoyl peroxide (2.5%)**		**Benzoyl peroxide (10%)**		
243 ↑ N=50 Parallel Mild/mod		**Total lesions change (%)**	Short (6)	Percent change: -45		Percent change: -39		**NS**
		Total lesions change (%)	Mid (8)	Percent change: -47		Percent change: -45		**NS**
	D.01.09			**Benzoyl peroxide (2.5%)**		**Benzoyl peroxide (5%)**		
242 ↑ N=52 Parallel Mild/mod		**Total lesions change (%)**	Short (6)	Percent change: -54		Percent change: -47		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
242 ↑ N=52 Parallel Mild/mod		**Total lesions change (%)**	Mid (8)	Percent change: -56		Percent change: -58		**NS**
	D.01.09			**Benzoyl peroxide (acetone)**		**Benzoyl peroxide (alcohol)**		
221 ↓ N=147 Parallel Mod		**Comedones change (%)**	Mid (8)	Percent change: -62		Percent change: -57		**NS**
		Papules change (%)	Mid (8)	Percent change: -56		Percent change: -56		**0.02**
		Pustules change (%)	Mid (8)	Percent change: -80		Percent change: -79		**NS**
	D.01.09			**Benzoyl peroxide (lotion)**		**Benzoyl peroxide (gel)**		
76 N=48 Parallel Mod		**Inflammatory (count)** Count location: Face (unspecified). Baseline counts: 32 (Target) / 28 (Comparator)	Short (4)	Percent Change*: -22	*.02*	Percent Change*: -32	*.01*	**NS***
		Non-inflammatory (count) Count location: Face (unspecified). Baseline counts: 57 (Target) / 58 (Comparator)	Short (4)	Percent Change*: -32	*.01*	Percent Change*: -17	*.01*	**NS***
		Overall change/patient (% improvement) Count location: Vas.	Short (4)	Measure: 19 (4.)		Measure: 22 (8.)		**NS***
		Severity (pillsbury) Count location: Face (unspecified).	Short (4)	Measure: 2 (1.1)	*.05*	Measure: 2 (1.1)	*.05*	**NS***
		Inflammatory (count) Count location: Face (unspecified). Baseline counts: 32 (Target) / 28 (Comparator)	Mid (8)	Percent Change*: -28	*.01*	Percent Change*: -39		**NS***
		Non-inflammatory (count) Count location: Face(unspecified). Baseline counts: 57 (Target) / 58 (Comparator)	Mid (8)	Percent Change*: -39	*.001*	Percent Change*: -28	*.001*	**NS***
		Overall change/patient (% improvement) Count location: Vas.	Mid (8)	Measure: 28 (10.)		Measure: 32 (20.)		**NS***
		Severity (pillsbury) Count location: Face (unspecified).	Mid (8)	Measure: 2 (0.5)	*.01*	Measure: 2 (0.5)	*.01*	**NS***
	D.01.09			**Benzoyl peroxide (water)**		**Benzoyl peroxide (alcohol)**		
118 N=49 Parallel split face		**Closed comedones change (%)**	Short (4)	Percent change: -77		Percent change: -76		**NS**
		Cysts change (%)	Short (4)	Percent change: -100		Percent change: -100		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
118 Parallel	N=49 split face	**Open comedones change (%)**	Short (4)	Percent change: -95		Percent change: -100		**NS**
		Papules change (%)	Short (4)	Percent change: -70		Percent change: -73		**NS**
		Pustules change (%)	Short (4)	Percent change: -92		Percent change: -100		**NS**
		Closed comedones change (%)	Mid (8)	Percent change: -88		Percent change: -90		**NS**
		Cysts change (%)	Mid (8)	Percent change: -100		Percent change: -100		**NS**
		Open comedones change (%)	Mid (8)	Percent change: -100		Percent change: -100		**NS**
		Papules change (%)	Mid (8)	Percent change: -80		Percent change: -82		**NS**
		Pustules change (%)	Mid (8)	Percent change: -100		Percent change: -100		**NS**
	D.05.01			**Benzoyl peroxide + erythromycin**		**Placebo**		
310 ↑ Parallel	N=92 Mild/mod	**Comedones (count)** Baseline counts: 7 (Target) / 6 (Comparator)	Short (4)	Percent Change*: -50	*.004*	Percent Change*: -18	*.001*	**NS**
		Inflammatory (count) Baseline counts: 21 (Target) / 18 (Comparator)	Short (4)	Percent Change*: -43	*.001*	Percent Change*: -19	*.003*	**0.008**
		Total lesions (count) Baseline counts: 28 (Target) / 29 (Comparator)	Short (4)	Percent Change*: -44	*.001*	Percent Change*: -31	*.001*	**NS**
		Comedones (count) Baseline counts: 7 (Target) / 6 (Comparator)	Mid (12)	Percent Change*: -46	*.06*	Percent Change*: 00	*.001*	**NS**
		Inflammatory (count) Baseline counts: 21 (Target) / 18 (Comparator)	Mid (12)	Percent Change*: -53	*.001*	Percent Change*: -26	*.02*	**0.01**
		Total lesions (count) Baseline counts: 28 (Target) / 29 (Comparator)	Mid (12)	Percent Change*: -51	*.001*	Percent Change*: -32	*.001*	**NS**
	D.05.02			**Erythromycin + benzoyl peroxide**		**Clindamycin phosphate**		
260 ↑ Parallel	N=205 Mild/mod	**Comedones (count)** Count location: Face.	Short (4)	Raw count: 17 (42.)		Raw count: 26 (42.)		**0.001**
		Inflammatory (count)	Short (4)	Raw count: 12 (7.)		Raw count: 13 (7.)		**NS***
		Comedones (count)	Mid (10)	Raw count: 14 (42.)		Raw count: 24 (42.)		**0.001**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
260 ↑ N=205 Parallel Mild/mod		**Inflammatory (count)** Count location: Face.	Mid (10)	Raw count: 9 (29.)		Raw count: 16 (29.)		**0.001**
		Overall change (score)	Mid (10)	Measure: 2 (1.7)		Measure: 2 (1.7)		**NS***
		Overall change (score)	Mid (10)	Measure: 3 (3.8)		Measure: 2 (3.8)		**NS***
	D.05.04			**Benzoyl peroxide + erythromycin**		**Zinc + erythromycin**		
62 ↓ N=72 Parallel Mod		**Clinical assessment/physician (score)**	Short (6)	Measure: 4 (0.9)		Measure: 3 (1.1)		**0.001**
		Comedones change (median %)	Short (6)	Measure: -76		Measure: -48		**NS**
		Inflammatory change (count/median)	Short (6)	Measure: -35		Measure: -18		**0.005**
		Clinical assessment/physician (score)	Mid (10)	Measure: 4 (0.7)		Measure: 3 (1.1)		**0.001**
		Comedones change (median %)	Mid (10)	Measure: -87		Measure: -60		**NS**
		Inflammatory change (count/median)	Mid (10)	Measure: -53		Measure: -27		**0.005**
	D.06.01			**Meclocycline + benzoyl peroxide**		**Benzoyl peroxide**		
30 ↑ N=102 Parallel Mod		**Comedones (count)** Count location: Face. Baseline counts: 9 (Target) / 10 (Comparator)	Short (6)	Percent Change*: -11		Percent Change*: -58		
		Papules (count) Count location: Face. Baseline counts: 21 (Target) / 21 (Comparator)	Short (6)	Percent Change*: -38		Percent Change*: -48		
		Pustules (count) Count location: Face. Baseline counts: 7 (Target) / 9 (Comparator)	Short (6)	Percent Change*: -17		Percent Change*: -56		
		Comedones (count) Count location: Face. Baseline counts: 9 (Target) / 10 (Comparator)	Mid (10)	Percent Change*: -44		Percent Change*: -68		**0.05**
		Papules (count) Count location: Face. Baseline counts: 21 (Target) / 21 (Comparator)	Mid (10)	Percent Change*: -43		Percent Change*: -62		**NS**
		Pustules (count) Count location: Face. Baseline counts: 7 (Target) / 9 (Comparator)	Mid (10)	Percent Change*: -23		Percent Change*: -58		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	D.08.01			**Benzoyl peroxide + miconazole**		**Benzoyl peroxide**		
111 ↓ N=52 Parallel Mod/sev		**Comedones (count)** Baseline counts: 61 (Target) / 53 (Comparator)	Short (4)	Percent Change*: -41	*sig*	Percent Change*: -49	*sig*	**NS**
		Irritation	Short (4)	Measure: 0 (0.5)		Measure: 1 (0.43)		**0.01**
		Irritation [Females]	Short (4)	Measure: 0 (0.42)		Measure: 1 (0.28)		**0.001**
		Irritation [Male]	Short (4)	Measure: 0 (0.57)		Measure: 1 (0.5)		**NS**
		Papules (count) Baseline counts: 10 (Target) / 8 (Comparator)	Short (4)	Percent Change*: -51	*sig*	Percent Change*: -63	*sig*	**NS**
		Pustules (count) Baseline counts: 4 (Target) / 4 (Comparator)	Short (4)	Percent Change*: -65	*sig*	Percent Change*: -79	*sig*	**NS**
		Total lesions (count) Baseline counts: 73 (Target) / 63 (Comparator)	Short (4)	Percent Change*: -44	*sig*	Percent Change*: -52	*sig*	**NS**
231 ↑ N=20 Parallel Mild/mod/sev		**Comedones change (geometric mean)** Count location: Face.	Mid (8)	Measure: -62 (28.)		Measure: -54 (63.)		**NS**
		Inflammatory change (geometric mean)	Mid (8)	Measure: -79 (15.)		Measure: -98 (60.)		**NS**
111 ↓ N=52 Parallel Mod/sev		**Comedones (count)** Baseline counts: 61 (Target) / 53 (Comparator)	Mid (12)	Percent Change*: -65	*sig*	Percent Change*: -72	*sig*	**NS**
		Irritation	Mid (12)	Measure: 0 (0.32)		Measure: 0 (0.46)		**NS**
		Irritation [Female]	Mid (12)	Measure: 0 (0.28)		Measure: 0 (0.49)		**NS**
		Irritation [Male]	Mid (12)	Measure: 0 (0.34)		Measure: 0 (0.42)		**NS**
		Papules (count) Baseline counts: 10 (Target) / 8 (Comparator)	Mid (12)	Percent Change*: -69	*sig*	Percent Change*: -69	*sig*	**NS**
		Pustules (count) Baseline counts: 4 (Target) / 4 (Comparator)	Mid (12)	Percent Change*: -81	*sig*	Percent Change*: -84	*sig*	**NS**
		Total lesions (count) Baseline counts: 73 (Target) / 63 (Comparator)	Mid (12)	Percent Change*: -66	*sig*	Percent Change*: -73	*sig*	**NS**
		Total lesions change (%)	Mid (12)	Percent change: -63 (27.1)	*sig*	Percent change: -69 (18.7)	*sig*	**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
111 ↓ N=52 Parallel Mod/sev		**Total lesions change [female] (%)** Between P-value: vs men.	Mid (12)	Percent change: -74 (15.9)		Percent change: -73 (13.9)		**0.02**
		Total lesions change [male] (%) Between P-value: vs women.	Mid (12)	Percent change: -50 (30.7)		Percent change: -66 (21.7)		**0.02**
	D.08.01			**Miconazole + benzoyl peroxide**		**Benzoyl peroxide**		
85 ↑ N=105 Parallel Mod		**Comedones (count)** Count location: Entire face. Baseline counts: 36 (Target) / 36 (Comparator)	Mid (8)	Percent Change*: -75		Percent Change*: -61		**0.001**
		Comedones (count)	Mid (12)	Percent Change*: -92		Percent Change*: -69		**0.001**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.